Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
15 pending office actions • 6 clients • 14 examiners • 11 art units • 0 of 15 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
BAUMGARTNER PATENT LAW has 16 pending office actions in Biotechnology & Pharmaceuticals and 671 career applications. Its resolved allowance rate is 73.25%, and the average is 2.66 office actions per allowance.
The profile provides both current docket information and historical outcome measures in the same technology area. The allowance rate is the reported result for resolved matters, while the action average indicates that allowed cases generally require more than one examination response. Practitioners can use the figures to plan active biotechnology prosecution while keeping the pending set distinct from the full application record.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 5 (33%) |
| §102 only | 1 (7%) |
| Multi-statute (no §101) | 8 (53%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.4% |
| PHILLIPS, FORREST M | 1 | 83.2% | +14.2% |
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| LARA, CAROLINE MONSERRAT | 1 | 85.7% | +16.7% |
| GRANT, ROBERT J | 1 | 76.3% | +17.5% |
| BRAM, STANLEY | 1 | 0.0% | +0.0% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | PHILLIPS, FORREST M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 161d overdue |
| 18522045 | COSMETIC SACHET FOR REDUCING AGE-RELATED SYMPTOMS IN HUMAN SKIN | BRAM, STANLEY | 56d |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | CANDELARIA, JULIANA IRENE | — |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | DUNN, LINDSAY MICHELLE | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | PHILLIPS, FORREST M | — |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — |
| 18638559 | FRUSTOCONICAL RECEIVER AND TRANSMITTER COILS FOR INDUCTIVE CHARGING OF LIGHT ELECTRIC VEHICLES | GRANT, ROBERT J | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | SPENCER, ANDREA LYNNE MORRIS | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Creative Medical Technologies | 9 |
| SOLAIRES ENTREPRISES INC. | 2 |
| Talk Systems Inc. | 1 |
| Wireless Pnc Inc. | 1 |
| Bloo Pharmapeutica Inc. | 1 |
| Salyx Medical Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 2859 | 2 |
| 1631 | 2 |
| 1638 | 2 |
| 2837 | 1 |
| 1633 | 1 |
| 1691 | 1 |
| 1644 | 1 |
| 1653 | 1 |
| 3794 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18936656 | PREFORMED FACEPIECE CUSHION FOR AN ACOUSTIC MASK AND COMBINATION THEREOF | Talk Systems Inc. | PHILLIPS, FORREST M | 2837 | §103 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | Creative Medical Technologies, Inc. | CONNORS, ALEXANDRA F | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | Creative Medical Technologies, Inc. | CANDELARIA, JULIANA IRENE | 1634 | §101§102§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | Creative Medical Technologies, Inc. | LARA, CAROLINE MONSERRAT | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18638559 | FRUSTOCONICAL RECEIVER AND TRANSMITTER COILS FOR INDUCTIVE CHARGING OF LIGHT ELECTRIC VEHICLES | Wireless Pnc Inc. | GRANT, ROBERT J | 2859 | §102 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18522045 | COSMETIC SACHET FOR REDUCING AGE-RELATED SYMPTOMS IN HUMAN SKIN | Bloo Pharmapeutica Inc. | BRAM, STANLEY | 1691 | §103 | Final Rejection | 56d | Pending | Nov 28, 2023 |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | Creative Medical Technologies, Inc. | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | Creative Medical Technologies, Inc. | NGUYEN, NGHI V | 1653 | §102§103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | Creative Medical Technologies, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | Creative Medical Technologies, Inc. | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18325851 | WEARABLE VITAL SIGNS MONITOR AND USE THEREOF | Salyx Medical Inc. | KERN, ASHLEIGH LAUREN | 3794 | §103 | Non-Final OA | 103d overdue | Pending | May 30, 2023 |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | Creative Medical Technologies, Inc. | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 83d | Pending | May 03, 2023 |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | Creative Medical Technologies, Inc. | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | 161d overdue | Pending | Apr 13, 2023 |
| 18181060 | WIRELESS CHARGING SYSTEM FOR LIGHT ELECTRIC VEHICLES | Solaires Entreprises Inc. | INSTONE, NATHANIEL JOSEPH | 2859 | §103§112 | Non-Final OA | — | Pending | Mar 09, 2023 |
| 17878804 | SOLAR POWERED ELECTRIC KICK SCOOTER | Solaires Entreprises Inc. | MEDANI, MOHAMED | 3611 | §103 | Final Rejection | 26d | Pending | Aug 01, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial73.2% of resolved applications prosecuted by Baumgartner Patent Law were allowed, across 671 applications in USPTO records.
2.66 office actions per allowed application on average.
15 pending office actions as of October 2026, for 6 clients, before 14 examiners in 11 art units.
